DALLAS, Aug. 11, 2015 /PRNewswire-iReach/ -- Rosellini Scientific, LLC (“RS” or “the Company”) an operational investment company, announced today that it received a Fast Track SBIR to develop a micro-perforated nanocomposite balloon for intravascular anti-restenotic drug delivery. RS is an operational investment company that specializes in the development of advanced medical device concepts at the intersection of implantable electronics, nanotechnology, and personalized medicine.
The Company licensed a patent portfolio from the inventor of the technology and principal investigator for the grant, Mark C. Bates, MD, DSc (hon). The portfolio includes three U.S. and seven international patents. Dr. Bates is the CEO of Nexeon MedSystems, a West Virginia-based medical device accelerator. With over 20 years of experience in medical device innovation, Dr. Bates has over 60 issued and pending US patents and has served as a founding member of a number of medtech companies that have exited for returns to shareholders.
“Current drug-coated balloons provide only passive drug delivery and require an excipient,” stated Dr. Bates. “Our system utilizes a proprietary nanocomposite balloon that enables precise pulse delivery of anti-restenotic therapeutic agents into the media. It is hoped that this method can be used for a number of different lipophilic as well as hydrophilic drugs while also eliminating the risk of decreased distal microvascular flow reserve associated with excipient embolization.”
The Company also announced the hire of Ron Conquest to serve as its COO. He currently serves on the Board of Directors for Nuviant Medical, Inc. and is Chairman of the Board of WindGen Energy Inc. Mr. Conquest’s domestic and international experience represents 40 years of corporate operations including numerous ground zero startups; investment banking; corporate mergers, acquisitions, and reorganizations; initial and secondary public offerings; public shell reverse mergers; legal, accounting, and SEC oversight; and corporate public relations and securities market making.
About Rosellini Scientific, LLC: Rosellini Scientific is an operational investment company dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The Company focused on ideas driven entirely by clinical need and has addressed these with telemedicine, active implantable devices, drug delivery combinations, interventional devices, nanotechnology, and the use of novel biomaterials. On the forefront of what is now called the “lean startup” model, Rosellini Scientific has focused exclusively on its rapid, highly capital-efficient development process since its inception in 2005 using proceeds from licensing and non-dilutive grants to finance the riskiest portions of clinical science.
Forward-Looking Statements: This news release contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company’s growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
Media Contact:Beth Rosellini, Rosellini Scientific, LLC, 2146426244, info@roselliniscientific.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Rosellini Scientific, LLC
Help employers find you! Check out all the jobs and post your resume.
